

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2020

Quantitative cardiac magnetic resonance T2 imaging offers ability to non-invasively predict acute allograft rejection in children

Neeta Sethi

Ashish Doshi

Tina Doshi

Russell Cross

Ileen Cronin

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors

Neeta Sethi, Ashish Doshi, Tina Doshi, Russell Cross, Ileen Cronin, Elena Amin, Joshua Kanter, Janet Scheel, Sairah Khan, Adrienne Campbell-Washburn, and Laura Olivieri

Original Article

Cite this article: Sethi N, Doshi A, Doshi T, Cross R, Cronin I, Amin E, Kanter J, Scheel J, Khan S, Campbell-Washburn A, and Olivieri L (2020) Quantitative cardiac magnetic resonance T2 imaging offers ability to non-invasively predict acute allograft rejection in children. *Cardiology in the Young* 30: 852–859. doi: [10.1017/S104795112000116X](https://doi.org/10.1017/S104795112000116X)

Received: 27 November 2019

Revised: 21 April 2020

Accepted: 22 April 2020

First published online: 27 May 2020


Keywords:

Paediatric; cardiac magnetic resonance; T2 mapping; heart transplant; allograft rejection

Author for correspondence:

Laura Olivieri, MD, 111 Michigan Avenue NW, W3-200, Washington, DC 20010, USA.
Tel: +1 202 476 2020; Fax: +1 202 476 3900.
E-mail: lolivieri@childrensnational.org

Quantitative cardiac magnetic resonance T2 imaging offers ability to non-invasively predict acute allograft rejection in children

Neeta Sethi¹ , Ashish Doshi^{1,2}, Tina Doshi³, Russell Cross¹, Ileen Cronin¹, Elena Amin⁴, Joshua Kanter¹, Janet Scheel⁵, Sairah Khan¹, Adrienne Campbell-Washburn⁶ and Laura Olivieri¹

¹Division of Cardiology, Children's National Hospital, Washington, DC 20010, USA; ²Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD 21218, USA; ³Division of Pain Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD 21205, USA; ⁴Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA; ⁵Division of Cardiology, St. Louis Children's Hospital, St. Louis, MO, 63110, USA and ⁶National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA

Abstract

Background: Monitoring for acute allograft rejection improves outcomes after cardiac transplantation. Endomyocardial biopsy is the gold standard test defining rejection, but carries risk and has limitations. Cardiac magnetic resonance T2 mapping may be able to predict rejection in adults, but has not been studied in children. Our aim was to evaluate T2 mapping in identifying paediatric cardiac transplant patients with acute rejection. **Methods:** Eleven paediatric transplant patients presenting 18 times were prospectively enrolled for non-contrast cardiac magnetic resonance at 1.5 T followed by endomyocardial biopsy. Imaging included volumetry, flow, and T2 mapping. Regions of interest were manually selected on the T2 maps using the middle-third technique in the left ventricular septal and lateral wall in a short-axis and four-chamber slice. Mean and maximum T2 values were compared with Student's t-tests analysis. **Results:** Five cases of acute rejection were identified in three patients, including two cases of grade 2R on biopsy and three cases of negative biopsy treated for clinical symptoms attributed to rejection (new arrhythmia, decreased exercise capacity). A monotonic trend between increasing T2 values and higher biopsy grades was observed: grade 0R T2 53.4 ± 3 ms, grade 1R T2 54.5 ms ± 3 ms, grade 2R T2 61.3 ± 1 ms. The five rejection cases had significantly higher mean T2 values compared to cases without rejection (58.3 ± 4 ms versus 53 ± 2 ms, p = 0.001). **Conclusions:** Cardiac magnetic resonance with quantitative T2 mapping may offer a non-invasive method for screening paediatric cardiac transplant patients for acute allograft rejection. More data are needed to understand the relationship between T2 and rejection in children.

Paediatric orthotopic heart transplantation is standard of care for end-stage heart failure from CHD or cardiomyopathy.¹ Acute allograft rejection remains the third leading cause of post-transplant mortality.² The Pediatric Heart Transplant Society database demonstrates that although there has been a decline in the rates of early rejection, the incidence of rejection with haemodynamic compromise or associated mortality has remained unchanged.³ Similarly, despite a decline in rates of late rejection, affected patients continue to be at significant risk for coronary vasculopathy, need for re-transplantation, and mortality.⁴

Early detection of allograft rejection can alter clinical course and is therefore essential in the care of a heart transplant patient. Periodic endomyocardial biopsy is the current gold standard test for rejection surveillance. However, its utility and diagnostic accuracy have been debated.^{5,6} Endomyocardial biopsy is a safe procedure but has risk of serious adverse events, including cardiac perforation, tricuspid valve injury, and arrhythmias.^{7,8} Also, endomyocardial biopsy with its blinded sampling solely of the right ventricle carries a chance of false-negative results.⁹ The right ventricle portion sampled is that which is easily reached, and therefore the same endomyocardial portions tend to be sampled. Over repeated catheterisations and years since transplantation, this leads to fibrosis which can additionally compromise diagnostic yield.⁸ This is especially of concern in children who require a lifetime of rejection surveillance.

There is a need for a non-invasive and more accurate method of detecting acute allograft rejection; however, echocardiography^{10,11} and serum biomarkers¹² have shown limited correlation. Cardiovascular magnetic resonance offers a diagnostic advantage in its ability to characterise the entire myocardium for evidence of scar or oedema using T1- and T2-weighted techniques.⁹ In addition, quantitative T2 mapping can uniquely assign a number to the degree of myocardial oedema. The T2 relaxation time is known to be prolonged in states of increased

myocardial oedema,^{13,14} such as in acute allograft rejection.^{15–17} This has been extensively studied in adult heart transplant patients,^{9,15,18,19} but to date there is limited data on its application in the paediatric population.

In addition, use of pre-contrast quantitative T1 mapping has been validated as a marker of myocardial fibrosis in children and adults with cardiomyopathy and can predict heart failure onset and mortality when prospectively applied.²⁰ T1 mapping also correlates with degree of histologic fibrosis in paediatric heart transplant recipients, which may provide prognostic insight into the degree of adverse myocardial remodelling and overall long-term graft health.²¹

The ability to non-invasively detect and monitor rejection within healthy myocardium of a transplanted heart may be influential in guiding clinical management and counselling. Our aim was to evaluate T2 mapping in identifying episodes of acute allograft rejection in a cohort of paediatric heart transplant patients. Our secondary aim was to compare this to native T1 data in these patients.

Materials and methods

With institutional review board approval and informed consent/assent, 18 encounters of 11 outpatient paediatric heart transplant patients were prospectively and consecutively enrolled from January 2016 to June 2018 at Children's National Hospital. This cohort underwent a comprehensive, non-contrast cardiac magnetic resonance scan on a 1.5-T magnetic resonance scanner (Aera, Siemens Healthcare, Erlangen, Germany), co-located with an interventional cardiac catheterisation suite. The patients were sedated under general anesthesia as was clinically indicated for the cardiac magnetic resonance and magnetic resonance-guided right heart catheterisation and endomyocardial biopsy sampling, standard of care at our institution.

At the completion of cardiac MRI, patients were transferred through a shared door into the adjoining cardiac catheterisation suite, where at least four endomyocardial biopsy samples were obtained from the right ventricular septum. The samples were stored in sterile saline and immediately sent for review in pathology, where tissue processing was performed according to routine clinical standards. Histopathology of endomyocardial biopsy samples was performed according to the International Society for Heart Lung Transplant classification of acute cellular rejection from grade 0R to 3R.²² Samples were additionally sent to an outside laboratory and graded by International Society for Heart Lung Transplant nomenclature of acute humoral rejection from pAMR 0 to pAMR 3.²³

Patient charts were reviewed for history of prior rejection, defined as any of the following since transplantation: acute cellular rejection with prior endomyocardial biopsy of grade 2R or higher, prior endomyocardial biopsy with acute humoral rejection, or prior treatment for clinical rejection.

Cardiac magnetic resonance included cine volumetric analysis using motion-corrected real-time cine imaging to obtain left and right ventricular ejection fractions (standard of care at our institution) and cardiac index.²⁴ Parametric maps of T2 and T1 were generated in one short-axis and one four-chamber slice. Table 1 lists the sequence parameters for the T1 and T2 map acquisitions,

Table 1. Sequence parameters for T2 mapping and T1 mapping using MOLLI technique

Sequence parameter	T2	T1 MOLLI HR < 90	T1 MOLLI HR > 90
FOV (mm)	360 × 270	360 × 270	360 × 270
Matrix	256 × 144	256 × 144	192 × 120
Resolution (mm)	1.4 × 1.4	1.4 × 1.9	1.9 × 2.3
Slice thickness (mm)	8	8	8
TE (ms)	1.18	1.12	1.01
TR (ms)	2.8	2.7	2.44
Flip angle (°)	18	35	35
Acquisition window (msec)	830	167	126
Parallel imaging acceleration	off	2	2
Partial Fourier	off	7/8	7/8

CMR sequence parameters for T2 mapping and T1 mapping using MOLLI technique, the latter was adjusted for patient's baseline heart rate to improve resolution for HR < 90 and HR > 90. FOV = field of view; HR = heart rate; TE = echo time; TR = repetition time.

including two types of MOLLI acquisitions based on heart rate (greater than and less than 90 beats per minute).

The MOLLI acquisition sampled the inversion recovery using a 5s (3s) 3s scheme for native T1 contrast during a breath hold. The different T1-weighted images were aligned prior to map creation using a motion correction algorithm used in several other large studies to minimise through-plane motion.^{25–27} The T2 map was obtained during a breath hold through use of T2-weighted SSFP images acquired with T2 prep times of 4 ms, 25 ms, and 55 ms.^{28,29}

Following cardiac magnetic resonance, parametric maps were de-identified and transferred for analysis (OsiriX, Bernex, Switzerland). Two regions of interest were manually traced by one blinded reviewer onto T1 and T2 parametric maps in the septal and left ventricle lateral wall of a mid-ventricular short-axis and four-chamber slice. The “middle-third” technique was used to generate an average, regional pixel value from that parametric map with care to avoid artefacts and blood pool at the endocardial border, consistent with earlier work in our lab.³⁰ A second, more experienced blinded reviewer examined the first reviewer's regions of interest tracings and made any necessary adjustments, which were usually minimal. Figure 1 demonstrates a native T2 map with the region of interest from a patient in the typical short-axis and four-chamber positions. The T1 and T2 mean values were noted for the septal and lateral positions for each short-axis and four-chamber slice. Each T1 and T2 mean value in the septal and lateral positions in the short-axis and four-chamber slices were averaged to generate an overall mean T1 and T2 value for each study, similar to work from other groups.^{15,19} T1 reference values are locally maintained per our institution's lab standard. T2 reference values are derived from prior published work.^{31–33}

All statistical analyses were performed in Stata 14 (StataCorp, USA). For analysis, acute allograft rejection was defined by decision to treat by the clinical team, i.e., an endomyocardial biopsy




Figure 1. T2 parametric map in the septal and left ventricular lateral wall of a four-chamber (a) and mid-ventricular short-axis (b) slice, with representative regions of interest drawn demonstrating the standard “middle-third” technique.

Table 2. Demographic table of heart transplant subjects

Patient	Number of studies performed	Case number	Initial cardiac diagnosis	Patient age at study (years)	Cardiac allograft age (years)
1	1	1	Myocarditis	17	6.4
2	2	2 and 6	RCM	4–5	3.1–3.9
3	1	4	Non-compaction cardiomyopathy	4	2.4
4	2	3 and 14	Anthracycline-induced DCM	15–17	0.6–2.7
5	3	5, 10, and 11	Familial DCM	13	1.0–1.4
6	1	8	Familial HCM	5	4.5
7	1	9	HLHS	17	17.4
8	1	12	PA/IVS with RVDCC	15	13.9
9	3	13, 17, and 18	DCM	10–11	8.5–9.8
10	2	15 and 16	DCM	16–17	14–14.7
11	1	7	PM-induced DCM	16	15.5

DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; HLHS = hypoplastic left heart syndrome; PA/IVS = pulmonary artery with intact ventricular septum; PM = pacemaker; RCM = restrictive cardiomyopathy; RVDCC = right ventricular-dependent coronary circulation.

with acute cellular rejection grade 2R or greater, an endomyocardial biopsy with acute humoral rejection, or presence of clinical symptoms. In order to identify potential differences between cases with and without acute allograft rejection, the two groups were compared using Student's t-tests. Characteristics analysed included mean T1 and T2 values, maximum T2 value, and maximum T1 value in the region of maximum T2 value. Exact logistic regression analyses were performed to estimate the odds of acute rejection as a function of each individual covariate. Due to small sample size, multivariable logistic regression analyses or a receiver operator characteristic curve were not performed. For all analyses, a p-value less than alpha of 0.05 was considered statistically significant.

Results

The 11 heart transplant patients ranged from 4 to 17 years old at the time of the study, with nearly equal gender distribution of six males with five females (Table 2). Cardiac allograft age ranged from 0.6 to 17.4 years at the time of the study. In six patients with operative data available, average total ischemic time during the transplant surgery was 271 ± 93 minutes, bypass time 197 ± 35 minutes, and cross-clamp time 64 ± 9 minutes. Two were

transplanted for critical CHD; nine patients were transplanted for primary or secondary cardiomyopathies: restrictive cardiomyopathy (n = 1), dilated cardiomyopathy (n = 3), hypertrophic cardiomyopathy (n = 1), non-compaction cardiomyopathy (n = 1), anthracycline-induced cardiomyopathy (n = 1), myocarditis (n = 1), and pacing-induced dilated cardiomyopathy (n = 1).

All patients were on a stable immunosuppressive regimen, with recent therapeutic tacrolimus or sirolimus levels prior to surveillance studies. Five patients had a prior history of biopsy-proven rejection (ranging from 0.25 to 13.9 years prior to cardiac magnetic resonance catheterisation for this study), with associated ventricular diastolic but not systolic dysfunction evident on cardiac catheterisation haemodynamics done at the time of positive endomyocardial biopsy results. There was normalisation of rejection-mediated ventricular diastolic function and clinical status in all patients prior to cardiac magnetic resonance catheterisation for this study. There was no patient history of significant non-adherence to immunosuppressive medications.

All endomyocardial biopsy samples from the 18 encounters were considered adequate and underwent pathology review. There were three cases with grade 1R, two cases of grade 2R, and none with

Table 3. CMR results for cases with and without acute allograft rejection

CMR ventricular function	No rejection (n = 13)	Rejection (n = 5)	p-value
LV end-diastolic volume, mL/m ² (SD)	67.0 (13.4)	62.8 (7.3)	NS, p = 0.53
LV end-systolic volume, mL/m ² (SD)	29.4 (8.2)	29.8 (9.8)	NS, p = 0.92
Stroke volume, mL/m ² (SD)	37.6 (7.0)	33.2 (6.1)	NS, p = 0.24
Ejection fraction, % (SD)	56.5 (5.8)	53.2 (11.5)	NS, p = 0.43
Cardiac index (QAo), L/min/m ² (SD)	3.2 (0.5)	2.9 (0.6)	NS, p = 0.3
Myocardial mass index, gm/m ² (SD)	53.2 (9.2)	49.2 (12.4)	NS, p = 0.47

CMR ventricular function results comparing all-cause rejection to no rejection. There are no differences in all CMR parameters between the two groups. CMR = cardiac magnetic resonance; LV = left ventricle; QAo = flow in the ascending aorta; NS = non-significant.




Figure 2. Average T2 values for grade 0R, grade 1R, and grade 2R biopsy categories. There is a monotonic trend with increasing T2 values and higher grades on endomyocardial biopsy (grade 0R T2 53.4 ± 3 ms; grade 1R T2 54.5 ± 3 ms; grade 2R averaged mean T2 61.3 ± 1 ms).

grade 3R. All but one sample underwent immunofluorescence for acute humoral rejection, and all returned negative or pAMR 0.

Five cases of acute allograft rejection occurred in three patients requiring treatment. Two episodes of rejection involved an asymptomatic patient with endomyocardial biopsy confirming rejection. The remaining three episodes of rejection had clinical symptoms and normal endomyocardial biopsy results. Coronary angiography performed in these three cases on the study date showed no evidence of coronary vasculopathy. Of these three, two were in one patient with two consecutive studies 6 months apart (cases 15 and 16) with clinical concerns of acute graft dysfunction with baseline tachycardia and reduced maximal oxygen uptake on exercise stress test. The third case of clinical rejection was a patient (case 7) with new ventricular tachycardia. After treatment of clinical rejection with intensified immunosuppression, both patients had resolution of these clinical symptoms.

Table 3 displays the averaged findings of ventricular systolic function on cardiac magnetic resonance, subdivided by cases of rejection. There were no patient limitations to image acquisition, and all cardiac magnetic resonance exams were analysed. There is no statistically significant difference in cardiac magnetic resonance parameters of cardiac systolic function in cases with none compared to cases with histologic or clinical rejection. To note, two cases of clinical rejection did have biventricular systolic dysfunction on cardiac magnetic resonance (discussed later). However, the other rejection cases have normal cardiac systolic function

and so there is no statistically significant difference in cardiac magnetic resonance cardiac systolic function between cases with and without rejection as a whole. There is also no significant difference indexed right ventricular end-diastolic volume in cases with none compared to cases with histologic or clinical rejection.

All T2 parametric maps were able to be analysed. Figure 2 displays the mean T2 value for the three endomyocardial biopsy categories: no rejection, grade 1R, and grade 2R. To note, the two cases of clinical rejection are included in the grade 0R group. There is a notable monotonic trend between increasing T2 values and higher endomyocardial biopsy grades: grade 0R averaged T2 53.4 ± 3 ms, grade 1R averaged T2 54.5 ± 3 ms, and grade 2R averaged T2 61.3 ± 1 ms.

The mean T2 values were evaluated between cases with and without acute allograft rejection, including the three clinical rejection cases and the two with grade 2R acute cellular rejection (Table 4). There is a statistically significant difference in the mean T2 value, with an average of 58 ± 4 ms in the rejection group versus 53 ± 2 ms in the non-rejection group (p = 0.001).

Figure 3 presents the 18 cases in order of ascending mean T2 time, with the cases of acute rejection highlighted. The two asterisked cases of acute cellular rejection both had mean T2 values greater than 60 ms. Notably, one patient serially studied accounted for both cases of acute cellular rejection (grade 2R). With treatment for rejection with intensified immunosuppression, the rejection improved (grade 1R) on a repeat encounter 16 months later. Cardiac magnetic resonance at that study case demonstrated a T2 time that had shortened from greater than 60 ms to 55 ms.

Table 4. T2 and T1 mapping results for cases with all-cause rejection compared to no rejection

CMR parameter	No rejection (n = 13)	Rejection (n = 5)	p-value
Mean T2, mean (SD)	53 (2.1)	58.3 (3.6)	p = 0.001
Maximum T2, mean (SD)	56.5 (2.5)	62.3 (3.4)	p = 0.001
	No rejection (n = 10)	Rejection (n = 5)	
Mean T1, mean (SD)	1023.8 (34)	1055.9 (70.5)	NS, p = 0.25
Maximum T1 at T2, mean (SD)	1023.7 (47)	1069.6 (62)	NS, p = 0.13

There is a statistically significant difference in the mean and maximum T2 values in cases of all-cause rejection compared to no rejection. There is no difference in the mean T1 or maximum T1 value at the region of the maximum T2 value between the two groups. CMR = cardiac magnetic resonance; NS = non-significant; SD = standard deviation.




Figure 3. The 18 studies in sequential order of ascending mean T2 value. The two cases of grade 2R are asterisked; both with a mean T2 value greater than 60 ms. The three clinical rejection cases are highlighted in red; two of the three had higher mean T2 values of 57.8–58.3 ms. A dotted line has been drawn at a T2 time of 56 ms; reported to be a cut-off to capture treatment-warranted rejection episodes based on a receiver operating curve in adult transplant patients.¹⁵

Of the three clinical rejection cases with normal endomyocardial biopsy (cases 7, 15, and 16), cases 15 and 16 had higher mean T2 values of 57.8–58.3 ms in both the left ventricular septal and lateral walls. Both cases also had biventricular systolic dysfunction on cardiac magnetic resonance (right ventricle ejection fraction 43–45%, left ventricle ejection fraction 42%), raising the possibility of false-negative endomyocardial biopsy results. To note, the T2 time of the right ventricular septal or lateral wall was not studied and so, it is uncertain whether the T2 time in the right ventricular apical septum where endomyocardial biopsy is typically obtained was suggestive of rejection or not.

In order to account for regional variability that the calculated mean T2 for each study may average out, the maximum mean T2 value for each study among the four slice positions was also evaluated (Table 4). The maximum T2 time in cases with all-cause rejection is significantly different than in non-rejection cases (62.3 ± 3 ms versus 56.5 ± 3 ms, $p = 0.001$).

Following exact logistic regression analysis, both mean and maximum T2 values are significantly associated with an episode of acute allograft rejection. The odds of acute rejection are 1.85 and 1.83 times greater for each one-unit increase in mean and maximum T2 values, respectively ($p = 0.004$ and 0.002 , respectively).

Fifteen of the 18 cases also had T1 mapping performed (Table 4). All T1 parametric maps were able to be analysed. There is no significant difference in the mean T1 in cases with and without rejection, 1056 ± 70.5 ms versus 1024 ± 34 ms ($p = 0.247$). The T1 value in the region of maximum T2 value in the two groups is also not significantly different, 1069.6 ± 62 ms versus 1023.7 ± 47 ms ($p = 0.13$). Using exact logistic regression, the mean T1 values and T1 values at the area of maximum T2 are not significantly associated with acute rejection ($p = 0.248$ and 0.136 , respectively).

Studies in cases with a history of prior rejection ($n = 8$) had a significantly higher mean T1 than cases with no prior rejection ($n = 7$), 1063 ± 42 ms compared to 1002 ± 35 ms ($p = 0.009$). In contrast, there is no significant difference in mean T2 value between cases with a history of prior rejection (56.2 ± 4.3 ms) versus cases with no prior rejection (53.8 ± 1.7 ms), $p = 0.196$. Notably, two of the five patients with a history of prior biopsy-proven rejection were in acute rejection at the time of the study and did have prolonged T2 times. However, the other three patients with a history of biopsy-proven rejection were not in rejection at the time of the study and had normal T2 times. This suggests that the prolonged T2 time in those two patients is

reflective of the acute rejection episode at the time of the study rather than related to the history of prior biopsy-proven rejection episodes.

Finally, there is no statistically significant correlation between T1 or T2 values and graft age (T1 correlation coefficient

rejection rather than intrinsic myocardial characteristics of the patients.

Finally, this pilot study obtained standard, limited imaging planes of the heart for T2 maps and was able to detect four of the five cases of rejection in limited views. It remains to be seen if more comprehensive imaging of the entire heart with T2 mapping could detect clinically significant rejection.

A larger multi-institutional trial is needed to obtain a larger sample size to better study the sensitivity and specificity of T2 mapping in detecting acute allograft rejection. A multi-institutional trial with standardised cardiac magnetic resonance pulse sequences will also enhance our understanding of the range in T2 time in normal control subjects as well as the variations in T2 time of heart transplant patients with and without rejection. In addition, there is a need to longitudinally study a large paediatric sample size to assess whether a prolonged T2 time reproducibly returns to baseline once a rejection episode resolves with intensified immunosuppression. Furthermore, collecting longitudinal data in a larger sample size will enable exploration of other potential cardiac magnetic resonance markers of graft rejection such as the rate of rise of T2 time above baseline in a patient as opposed to the absolute T2 time in itself. In conclusion, this study is the first to demonstrate the novel use of cardiac magnetic resonance with quantitative T2 mapping as a non-invasive method in the surveillance of paediatric cardiac transplant patients for acute allograft rejection. A larger multi-institutional investigation is needed for further validation, but this early data suggest that T2 mapping is a promising imaging biomarker for monitoring myocardial oedema related to acute allograft rejection. Secondly, we found higher native T1 values in patients with a history of allograft rejection, indicating that T1 mapping may be a non-invasive imaging biomarker for myocardial fibrosis and perhaps overall graft health.

Acknowledgements. None.

Financial support. This work was supported by the National Heart, Lung, and Blood Institute (contract number NHLBI-CSB-(HL)-2014-013-JML).

Conflicts of interest. None.

Ethical standards. The authors assert that all procedures contributing to this work comply with the ethical standards with the Helsinki Declaration of 1975, as revised in 2008, and have been approved by the institutional review committee at Children's National Hospital. Informed consent: Informed consent/assent was obtained from all individual participants included in the study.

References

1. Thrush PT, Hoffman TM. Pediatric heart transplantation-Indications and outcomes in the current era. *J Thorac Dis.* 2014; 6: 1080–1096. doi: [10.3978/j.issn.2072-1439.2014.06.16](https://doi.org/10.3978/j.issn.2072-1439.2014.06.16).
2. Dipchand AI, Rossano JW, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Pediatric Heart Transplantation Report - 2015; Focus Theme: early Graft Failure. *J Hear Lung Transplant.* 2015; 34: 1233–1243.
3. Gossett JG, Canter CE, Zheng J, et al. Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study. *J Hear Lung Transplant.* 2010; 29: 625–632. doi: [10.1016/j.healun.2009.12.009](https://doi.org/10.1016/j.healun.2009.12.009).
4. Ameduri RK, Zheng J, Schechtman KB, et al. Has late rejection decreased in pediatric heart transplantation in the current era? A multi-institutional study. *J Hear Lung Transplant.* 2012; 31: 980–986. doi: [10.1016/j.healun.2012.05.016](https://doi.org/10.1016/j.healun.2012.05.016).
5. Vermes E, Pantaleon C, Ucheux J, Aupart M, Cazeneuve N, Brunereau L. Cardiac Magnetic Resonance in heart transplant patients: diagnostic value

of quantitative tissue markers (T2 mapping and ECV) for acute cardiac rejection diagnosis. *J Cardiovasc Magn Reson.* 2016; 18: 1–12. <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L72182792%5Cnhttp://rug.on.worldcat.org/atoztitles/link/?sid=EMBASE&issn=10976647&id=doi:&title=Cardiac>

23. Berry GJ, Burke MM, Andersen C, et al. The 2013 international society for heart and lung transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. *J Hear Lung Transplant*. 2013; 32: 1147–1162. doi: [10.1016/j.healun.2013.08.011](https://doi.org/10.1016/j.healun.2013.08.011).
24. Cross R, Olivieri L, O'Brien K, Kellman P, Xue H, Hansen M. Improved workflow for quantification of left ventricular volumes and mass using free-breathing motion corrected cine imaging. *J Cardiovasc Magn Reson*. 2016; 18: 1–12. doi: [10.1186/s12968-016-0231-8](https://doi.org/10.1186/s12968-016-0231-8).
25. Kellman P, Hansen MS. T1-mapping in the heart: accuracy and precision. *J Cardiovasc Magn Reson*. 2014; 16: 1–20. doi: [10.1186/1532-429X-16-2](https://doi.org/10.1186/1532-429X-16-2).
26. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. *J Cardiovasc Magn Reson*. 2013; 15: 92. doi: [10.1186/1532-429X-15-92](https://doi.org/10.1186/1532-429X-15-92).
27. Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular. *J Cardiovasc Magn Reson*. 2017; 19: 1–25. doi: [10.1186/s12968-017-0389-8](https://doi.org/10.1186/s12968-017-0389-8).
28. Hammer-Hansen S, Ugander M, Hsu L-Y, et al. Distinction of salvaged and infarcted myocardium within the ischaemic area-at-risk with T2 mapping. *Eur Hear J - Cardiovasc Imaging*. 2014; 15: 1048–1053. doi: [10.1093/ehjci/jeu073](https://doi.org/10.1093/ehjci/jeu073).
29. Giri S, Chung Y-C, Merchant A, et al. T2 quantification for improved detection of myocardial edema. *J Cardiovasc Magn Reson*. 2009; 11: 56. doi: [10.1186/1532-429X-11-56](https://doi.org/10.1186/1532-429X-11-56).
30. Olivieri LJ, Kellman P, McCarter RJ, Cross RR, Hansen MS, Spurney CF. Native T1 values identify myocardial changes and stratify disease severity in patients with Duchenne muscular dystrophy. *J Cardiovasc Magn Reson*. 2017; 18: 72. doi: [10.1186/s12968-016-0292-8](https://doi.org/10.1186/s12968-016-0292-8).
31. Hagio T, Huang C, Abidov A, et al. T2 mapping of the heart with a double-inversion radial fast spin-echo method with indirect echo compensation. *J Cardiovasc Magn Reson*. 2015; 17: 24. doi: [10.1186/s12968-015-0108-2](https://doi.org/10.1186/s12968-015-0108-2).
32. Sparrow P, Amirabadi A, Sussman MS, Paul N, Merchant N. Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. *J Magn Reson Imag*. 2009; 30: 942–946. doi: [10.1002/jmri.21918](https://doi.org/10.1002/jmri.21918).
33. Blume U, Lockie T, Stehning C, et al. Interleaved T(1) and T(2) relaxation time mapping for cardiac applications. *J Magn Reson Imag*. 2009; 29: 480–487. doi: [10.1002/jmri.21652](https://doi.org/10.1002/jmri.21652).
34. Greenway SC, Dallaire F, Kantor PF, et al. Magnetic resonance imaging of the transplanted pediatric heart as a potential predictor of rejection. *World J Transplant*. 2016; 6: 751. doi: [10.5500/wjt.v6.i4.751](https://doi.org/10.5500/wjt.v6.i4.751).
35. Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imagin. *J Cardiovasc Magn Reson*. 2017; 19: 1–3. doi: [10.1186/s12968-017-0389-8](https://doi.org/10.1186/s12968-017-0389-8).
36. Aherne T, Tscholakoff D, Finkbeiner W, et al. Magnetic resonance imaging of cardiac transplants: the evaluation of rejection of cardiac allografts with and without immunosuppression. *Circulation*. 1986; 74: 145–156. <http://www.ncbi.nlm.nih.gov/pubmed/3518982>.
37. Aherne T, Yee ES, Tscholakoff D, Gollin G, Higgins C, Ebert PA. Diagnosis of acute and chronic cardiac rejection by magnetic resonance imaging: a non-invasive in-vivo study. *J Cardiovascular Surg*. 1988; 29: 587–590.
38. Tscholakoff D. Magnetic resonance tomography of the heart. Experimental study of a non-invasive characterization of myocardial tissue. *Rofo*. 1987; 146: 82–88.